Q3 Earnings Forecast for ELVN Issued By HC Wainwright

Enliven Therapeutics, Inc. (NASDAQ:ELVN) – Equities researchers at HC Wainwright issued their Q3 2026 earnings per share estimates for Enliven Therapeutics in a note issued to investors on Monday, October 19th. HC Wainwright analyst R. Burns expects that the company will earn ($0.41) per share for the quarter. HC Wainwright has a “Buy” rating and a $73.00 price objective on the stock. The consensus estimate for Enliven Therapeutics’ current full-year earnings is ($1.81) per share. HC Wainwright also issued estimates for Enliven Therapeutics’ Q4 2026 earnings at ($0.46) EPS, FY2026 earnings at ($1.74) EPS, Q1 2027 earnings at ($0.48) EPS, Q2 2027 earnings at ($0.50) EPS, Q3 2027 earnings at ($0.52) EPS and Q4 2027 earnings at ($0.55) EPS.

Enliven Therapeutics (NASDAQ:ELVN) last released its quarterly earnings data on Wednesday, August 5th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.10).

A number of other equities analysts have also recently commented on the stock. Guggenheim reaffirmed a “buy” rating on shares of Enliven Therapeutics in a research report on Thursday, October 8th. JPMorgan Chase & Co. assumed coverage on shares of Enliven Therapeutics in a report on Thursday, October 1st. They issued an “overweight” rating and a $75.00 price objective on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Enliven Therapeutics in a research report on Thursday, October 15th. Morgan Stanley assumed coverage on shares of Enliven Therapeutics in a research report on Friday, October 2nd. They issued an “overweight” rating and a $70.00 price objective on the stock. Finally, JonesTrading raised their target price on shares of Enliven Therapeutics from $45.00 to $70.00 and gave the stock a “buy” rating in a research note on Monday, June 29th. Ten analysts have rated the stock with a Buy rating and two have given a Sell rating to the stock. Based on data from MarketBeat, Enliven Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $75.44.

Enliven Therapeutics Price Performance

ELVN stock opened at $41.25 on Wednesday. Enliven Therapeutics has a 1-year low of $14.78 and a 1-year high of $62.32. The business’s 50 day simple moving average is $51.25 and its 200 day simple moving average is $47.98.

Insider Activity

In other news, CFO Benjamin Hohl sold 6,018 shares of the stock in a transaction that occurred on Thursday, September 17th. The stock was sold at an average price of $50.35, for a total transaction of $303,006.30. Following the transaction, the chief financial officer owned 38,000 shares in the company, valued at approximately $1,913,300. This trade represents a 13.67% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mika K. Derynck sold 158,795 shares of Enliven Therapeutics stock in a transaction that occurred on Tuesday, August 4th. The stock was sold at an average price of $60.21, for a total value of $9,561,046.95. Following the sale, the director directly owned 87,373 shares of the company’s stock, valued at approximately $5,260,728.33. The trade was a 64.51% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 183,831 shares of company stock valued at $10,823,298. 3.00% of the stock is owned by insiders.

Institutional Trading of Enliven Therapeutics

Several institutional investors have recently added to or reduced their stakes in the company. BlackRock Inc. acquired a new position in shares of Enliven Therapeutics during the second quarter worth $221,255,000. First Light Asset Management LLC lifted its position in shares of Enliven Therapeutics by 574.1% during the 2nd quarter. First Light Asset Management LLC now owns 1,360,750 shares of the company’s stock valued at $69,058,000 after acquiring an additional 1,158,883 shares during the period. Assenagon Asset Management S.A. boosted its holdings in Enliven Therapeutics by 276.4% in the third quarter. Assenagon Asset Management S.A. now owns 1,153,973 shares of the company’s stock worth $52,898,000 after acquiring an additional 847,399 shares in the last quarter. Siren L.L.C. bought a new stake in Enliven Therapeutics during the 1st quarter valued at $29,252,000. Finally, Jupiter Topco LLC acquired a new stake in shares of Enliven Therapeutics in the 2nd quarter worth about $30,617,000. 95.08% of the stock is currently owned by institutional investors.

About Enliven Therapeutics

Enliven Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing targeted therapies for patients with cancer. The company uses small-molecule drug discovery and development to pursue treatments designed to address validated cancer targets and improve patient outcomes.

Enliven’s pipeline includes ELVN-001, an investigational BCR-ABL1 tyrosine kinase inhibitor being developed for the treatment of chronic myeloid leukemia, and ELVN-002, an investigational HER2 inhibitor intended for use in patients with HER2-positive solid tumors.